Clinical trials: Cancer, Bladder
Muscle-invasive Bladder Urothelial Carcinoma
A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer
This is a prospective, open-label, single-center, single-arm clinical study. Plans to enroll 45 MIBC patients with clinical stage T2-T4aN0M0 and HER2-positive (IHC 1+/2+/3+) status.
- Trial name
- NCT07279597
- Testing
- RC48-ADC + Toripalimab
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Bladder Cancer
Bladder Tumor Biopsy Study to Improve Preoperative Determination of Stage and Grade
To assess whether the addition of a bladder tumor biopsy improves the level of agreement between the pretreatment endoscopic impression and the final postoperative pathology determination of stage and grade in non-muscle-invasive…
- Trial name
- NCT02992990
- Testing
- Bladder tumor biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor College of Medicine
Bladder Neoplasms, Ureteral Neoplasms
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
Phase 2B, multicenter study evaluating the safety and efficacy of weekly TOCOSOL Paclitaxel in taxane-naive patients receiving second line chemotherapy for metastatic or locally advanced, unresectable transitional cell carcinoma…
- Conditions
- Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Carcinoma, Transitional Cell
- Trial name
- NCT00077688
- Testing
- TOCOSOL Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Achieve Life Sciences
Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
This is an interventional, prospective multicenter, open-label, phase II study in patients after curative surgery for BTC in a classic adjuvant situation, consisting of a two arm feasibility pilot part with a randomized…
- Conditions
- Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma
- Trial name
- NCT05239169
- Testing
- Durvalumab, Tremelimumab, Capecitabine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Breast Cancer, Sarcoma
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently…
- Conditions
- Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer
- Trial name
- NCT06580002
- Testing
- Riluzole
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of California, Irvine
Bladder Cancer
Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of selenium and vitamin E may stop cancer from growing or coming back.
- Trial name
- NCT00553345
- Testing
- selenium, vitamin E, chemoprevention
- Where
- United Kingdom
- Volunteers
- 515 people
- Sponsor
- University of Birmingham
Gall Bladder Carcinoma
Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)
to study role of chemotherapy treatment for gall bladder cancer before surgery as compared to surgery directly
- Trial name
- NEOGB (NCT06712420)
- Testing
- neoadjuvant chemotherapy, curative surgery
- Where
- 3 sites in India
- Volunteers
- 114 people
- Sponsor
- Rajiv Gandhi Cancer Institute & Research Center, India
Bladder Cancer, Liquid Biopsy
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
This study evaluates whether urinary tumor DNA (utDNA) testing, together with clinical, pathologic, and radiographic assessment, can help guide treatment discontinuation and active surveillance in patients with unresectable…
- Conditions
- Bladder Cancer, Liquid Biopsy, Immunotherapy
- Trial name
- NCT07475403
- Testing
- Systemic immunotherapy
- Where
- 3 sites in China
- Volunteers
- 53 people
- Sponsor
- Tianjin Medical University Second Hospital
Bladder Cancer, Prostate Cancer
Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
The objective of this pilot cohort study is to investigate associations between CIN and changes in gut microbiome composition profiles.
- Conditions
- Bladder Cancer, Prostate Cancer, Testicular Cancer, Bladder Carcinoma
- Trial name
- NCT05819827
- Testing
- Blood and Tissue
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Bladder Cancer
Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
RATIONALE: Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01222676
- Testing
- cisplatin, gemcitabine hydrochloride, sorafenib tosylate
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc)
Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers
The goal of this prospective observational study is to evaluate whether Gallium-68 Fibroblast Activation Protein Inhibitor (FAPI) PET/CT can improve detection, staging, and recurrence assessment in adult patients (≥18 years) with…
- Trial name
- FAPi-2 (NCT07337850)
- Testing
- gallium-68-Fibroblast Activation Protein Inhibitor
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Centre
Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well vorinostat works in treating patients with locally recurrent or metastatic cancer of…
- Conditions
- Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00363883
- Testing
- vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with…
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer
- Trial name
- NCT03629756
- Testing
- Etrumadenant, Zimberelimab
- Where
- 15 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Arcus Biosciences, Inc.
Bladder (Urothelial, Transitional Cell) Cancer
Observational Clinical Study of Patients With Muscle - Invasive Bladder Cancer Undergoing Bladder Preservation Therapy After Neoadjuvant Therapy
The goal of this observational study is to evaluate the safety and efficacy of neoadjuvant therapy followed by bladder - preserving TMT in patients with MIBC.
- Trial name
- NCT07053722
- Testing
- NA-TMT
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Urinary Bladder Neoplasms, Ureteral Neoplasms
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
This is a single arm two-stage phase II study with crizotinib (Xalkori®) in the treatment of subjects with metastatic urothelial cancer of the bladder, upper (ureter or renal pelvis) or lower (urethra) urinary tracts.
- Conditions
- Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms
- Trial name
- NCT02612194
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Wake Forest University Health Sciences
Melanoma, Breast Cancer
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying…
- Conditions
- Melanoma, Breast Cancer, Renal Cell Carcinoma, Urinary Bladder Cancer
- Trial name
- Serpentine (NCT05621837)
- Testing
- MDSC quantification
- Where
- Italy
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Neoplasms, Urinary Bladder
Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer
This study aims to analyze the incidence of expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME tumor antigens in cancer tissue from patients with pathologically demonstrated bladder cancer.
- Trial name
- NCT01706185
- Testing
- Data acquisition and analysis
- Where
- Belgium
- Volunteers
- 156 people
- Sponsor
- GlaxoSmithKline
Bladder Cancer
Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC
This study assesses the effect of sequential radiation and durvalumab immunotherapy given as treatment prior to surgery with radical cystectomy for bladder cancer.
- Trial name
- RADIANT (NCT04543110)
- Testing
- Durvalumab, Immune Modulating Radiation
- Where
- 4 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Ottawa Hospital Research Institute
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
This phase Ib/II trial studies the side effects, best dose, and effectiveness of enfortumab vedotin (EV) in combination with pembrolizumab and radiation therapy for treating patients with muscle invasive bladder cancer.
- Conditions
- Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT06470282
- Testing
- Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.